489 related articles for article (PubMed ID: 31238042)
1. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
Huapaya JA; Silhan L; Pinal-Fernandez I; Casal-Dominguez M; Johnson C; Albayda J; Paik JJ; Sanyal A; Mammen AL; Christopher-Stine L; Danoff SK
Chest; 2019 Nov; 156(5):896-906. PubMed ID: 31238042
[TBL] [Abstract][Full Text] [Related]
2. Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis.
Morisset J; Johannson KA; Vittinghoff E; Aravena C; Elicker BM; Jones KD; Fell CD; Manganas H; Dubé BP; Wolters PJ; Collard HR; Ryerson CJ; Ley B
Chest; 2017 Mar; 151(3):619-625. PubMed ID: 27816444
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
[TBL] [Abstract][Full Text] [Related]
4. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis.
Lombardi F; Stewart I; Fabbri L; Adams W; Kawano-Dourado L; Ryerson CJ; Jenkins G;
BMJ Open Respir Res; 2024 Feb; 11(1):. PubMed ID: 38413120
[TBL] [Abstract][Full Text] [Related]
6. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis.
Mira-Avendano IC; Parambil JG; Yadav R; Arrossi V; Xu M; Chapman JT; Culver DA
Respir Med; 2013 Jun; 107(6):890-6. PubMed ID: 23517887
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.
Fischer A; Brown KK; Du Bois RM; Frankel SK; Cosgrove GP; Fernandez-Perez ER; Huie TJ; Krishnamoorthy M; Meehan RT; Olson AL; Solomon JJ; Swigris JJ
J Rheumatol; 2013 May; 40(5):640-6. PubMed ID: 23457378
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis.
Zheng JN; Yang QR; Zhu GQ; Pan L; Xia JX; Wang Q
Mod Rheumatol; 2020 Jul; 30(4):687-695. PubMed ID: 31269839
[No Abstract] [Full Text] [Related]
9. Treatment of primary sjögren's syndrome-related interstitial lung disease: a retrospective cohort study.
Amlani B; Elsayed G; Barvalia U; Kanne JP; Meyer KC; Sandbo N; Li Z; McCoy SS
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):136-147. PubMed ID: 33093777
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.
Swigris JJ; Olson AL; Fischer A; Lynch DA; Cosgrove GP; Frankel SK; Meehan RT; Brown KK
Chest; 2006 Jul; 130(1):30-6. PubMed ID: 16840379
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
[TBL] [Abstract][Full Text] [Related]
12. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis-A single-centre experience.
Fiddler CA; Simler N; Thillai M; Parfrey H
Clin Respir J; 2019 Dec; 13(12):791-794. PubMed ID: 31464073
[TBL] [Abstract][Full Text] [Related]
13. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease.
Huapaya JA; Hallowell R; Silhan L; Pinal-Fernandez I; Casal-Dominguez M; Johnson C; Albayda J; Paik JJ; Lin CT; Hussien A; Mammen AL; Christopher-Stine L; Danoff SK
Respir Med; 2019; 154():6-11. PubMed ID: 31176796
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
Ma X; Tang R; Luo M; Zeng Z; Shi Y; Tang B; Xiao R
Clin Rheumatol; 2021 Aug; 40(8):3185-3193. PubMed ID: 34080081
[TBL] [Abstract][Full Text] [Related]
16. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
18. Interstitial lung disease in antisynthetase syndrome without clinical myositis.
Sundaragiri PR; Vallabhajosyula S; Kanaan JP
BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24700049
[No Abstract] [Full Text] [Related]
19. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease.
Cavagna L; Caporali R; Abdì-Alì L; Dore R; Meloni F; Montecucco C
J Rheumatol; 2013 Apr; 40(4):484-92. PubMed ID: 23418387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
